07/16/2026
π Exciting news for the rare disease community!
Children's Hospital of Philadelphia has secured a five-year, up to $38.9 million award from ARPA-H's THRIVE program to advance personalized gene editing therapies for rare, liver-related genetic disorders, including urea cycle disorders, organic acidemias, severe clotting disorders, and hemophilia A.
We're proud that our own Kiran Musunuru, MD, PhD, MPH, ML, MRA, Co-Director of the Orphan Disease Center (a CHOP and Penn Medicine partnership), is part of the team leading this work, alongside CHOP's Rebecca Ahrens-Nicklas, MD, PhD and Lindsey A. George, MD.
This award builds on the landmark treatment of baby KJ Muldoon, whose personalized CRISPR gene-editing therapy, led by Dr. Ahrens-Nicklas and Dr. Musunuru, was the first of its kind in the world. Now that breakthrough is being scaled into a platform that could reach many more children with life-threatening rare diseases.
Congratulations to the whole team. This is exactly the kind of collaborative science the Orphan Disease Center exists to support. π§¬
Read more: https://www.chop.edu/news/childrens-hospital-philadelphia-secures-five-year-389-million-arpa-h-award-advance
CHOP announced today that it has been awarded a five-year up to $38.9 million award from the Advanced Research Projects Agency for Health (ARPA H) THRIVE program to support the advancement of personalized gene therapy. Rebecca Ahrens-Nicklas, MD, PhD Childrenβs Hospital of Philadelphia (CHOP) anno...